Search clinical trials for: CD19 Universal CAR-γδ T Cells

Total 888 results

Chinese PLA General Hospital

Unknown

A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy

Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T ACI

China
Sinobioway Cell Therapy Co., Ltd.

Unknown

Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer (EECSC)

Stomach Neoplasms

China
Peking University
University of Florida

Unknown

CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)

Lymphomas

China, United States
City of Hope Medical Center
National Cancer Institute (NCI); California Institute for Regenerative Medicine...

Recruiting

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases

Breast Cancer | HER2-positive Breast Cancer | Malignant Neoplasm | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the Leptomeninges

United States
Wuhan Union Hospital, China

Not yet recruiting

Study of SYS6020 in BCMA-positive Multiple Myeloma

Multiple Myeloma
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
University of Pennsylvania
Prostate Cancer Foundation

Recruiting

TmPSMA-02 in mCRPC

Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies

Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | T-cell Acute Lymphoblastic Leukemia | T Lymphoblastic Leukemia/Lymphoma

China
The First Affiliated Hospital of Soochow University
Affiliated Hospital of Jiangnan University; The Affiliated Nanjing Drum Tower... and other collaborators

Recruiting

CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma

Refractory and Relapsed T Cell Lymphoma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor

Gastric Cancer | Lung Cancer | Osteosarcoma | Neuroblastoma
University of Pennsylvania

Completed

cMet CAR RNA T Cells Targeting Breast Cancer

Metastatic Breast Cancer | Triple Negative Breast Cancer

United States
Wuhan Union Hospital, China
Wuhan Bio-Raid Biotechnology Co., Ltd.

Unknown

Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
Sinobioway Cell Therapy Co., Ltd.
Children's Hospital of Fudan University; Nanjing Children's Hospital

Unknown

Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children

Relapsed or Refractory Neuroblastoma

China
The Second Hospital of Nanjing Medical University

Unknown

A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application

Nasopharyngeal Neoplasms

China
Changhai Hospital
CARsgen Therapeutics Co., Ltd.

Unknown

Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma | Advanced Gastric Adenocarcinoma

China
University of Pennsylvania
Children's Hospital of Philadelphia

Terminated

Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Henan Cancer Hospital
Henan Hualong Biotechnology Company

Unknown

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

B Cell Lymphoma | B Cell Leukemia | Refractory | Relapsed

China
Sheba Medical Center

Recruiting

CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression

Acute Myeloid Leukemia

Israel
Beijing Boren Hospital

Recruiting

Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou Anjie Biomedical Technology Co., Ltd.

Completed

PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer

Advanced Breast Cancer | Breast Neoplasm Malignant Female

China
Technische Universität Dresden
German Cancer Research Center

Recruiting

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies (CARLOTTA01)

Neoplasms | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Germany
Hrain Biotechnology Co., Ltd.
First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng...

Recruiting

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Multiple Myeloma

China
RenJi Hospital
CARsgen Therapeutics Co., Ltd.

Unknown

CD19-redirected Autologous Cells (CAR-CD19 T Cells)

CD19 Positive Malignant B-cell Leukemia and Lymphoma

China
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein Overexpression

United States
Stephan Grupp MD PhD
Children's Hospital of Philadelphia

Recruiting

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

B Cell Acute Lymphoblastic Leukemia (B-ALL) | B Lineage Lymphoblastic Lymphoma

United States
XuYan

Recruiting

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Chongqing Precision Biotech Co., Ltd

Recruiting

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Neoplasm, Plasma Cell

China
Incyte Corporation

Completed

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Cytokine Release Syndrome

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Relapsed Acute Myeloid Leukemia

United States
920th Hospital of Joint Logistics Support Force...

Recruiting

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Bioceltech Therapeutics, Ltd.

Recruiting

Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL

T Cell Lymphoblastic Lymphoma

China
Beijing Tiantan Hospital

Recruiting

Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma

Glioblastoma

China
Chinese PLA General Hospital

Recruiting

TGFβR-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors

Solid Tumor, Adult | EGFR Overexpression

China
Wuhan Sian Medical Technology Co., Ltd
Wuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaborators

Recruiting

Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
Chinese PLA General Hospital

Recruiting

CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas (CART30)

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

China
Memorial Sloan Kettering Cancer Center
Takeda

Active, not recruiting

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Burkitt's Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Indolent Non-Hodgkin Lymphoma | Primary CNS Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma

United States
Shenzhen Geno-Immune Medical Institute

Unknown

Intervention of CAR-T Against Cervical Cancer

Cervical Cancer

China
Fudan University
Guangzhou Bioresette Biomedical Technology Co., Ltd.; Chaosu Hu，Principal Investigator...

Recruiting

Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Xuzhou Medical University
Yake Biotechnology Ltd.

Recruiting

Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma (CAR-T)

Multiple Myeloma

China
Jian-Kun Hu

Recruiting

Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)

Metastases, Neoplasm | Neoplasm Seeding | Neoplasm, Stomach

China
Shanghai East Hospital
Bio4T2 LLC

Active, not recruiting

A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors

Advanced Solid Tumor

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

Platinum-Resistant Ovarian Carcinoma

United States
University College, London
Deutsche Krebshilfe e.V., Bonn (Germany); European Union; The Leukemia and Lymphoma... and other collaborators

Terminated

CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL) (CD19TPALL)

Acute Lymphoblastic Leukemia

United Kingdom, Germany
Beijing 302 Hospital
Beijing GD Initiative Cell Therapy Technology Co., Ltd.; Chinese Academy of...

Not yet recruiting

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma
Zhejiang University

Recruiting

Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors

Advanced Solid Tumors

China
Roger Williams Medical Center
University of Colorado, Denver; Sorrento Therapeutics, Inc.

Completed

CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer (HITM-SURE)

Liver Metastases

United States
University College, London

Completed

CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation (CARD)

CD19+ Malignancies: Relapse Post-allogeneic Transplant

United Kingdom
Miltenyi Biomedicine GmbH
ICON plc

Active, not recruiting

Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)

B-cell Non Hodgkin Lymphoma

Germany
Zhejiang University
UTC Therapeutics Inc.

Recruiting

UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

Mesothelin-positive Advanced Malignant Solid Tumors

China
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Refractory Acute Lymphoblastic Leukemia | Philadelphia-Negative ALL | Philadelphia-Positive ALL | Refractory Acute Lymphoblastic Leukemia (ALL) | Relapsed ALL, Adult | Refractory Acute Lymphoid Leukemia in Relapse

United States

Search clinical trials for: CD19 Universal CAR-γδ T Cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations